Why did RNXT's EPS remain flat throughout 2023?
4/12/2025 07:33pm
RenovoRx's EPS remained flat throughout 2023 due to a combination of factors:
1. **Financial Performance**: The company's EPS was -$0.99 for 2022 Q4 and -$1.09 for 2023 Q4, indicating a decline in earnings per share over the period.
2. **Revenue Challenges**: Avantor Inc, for instance, faced a slight decline in net sales, missing the estimated revenue. Similarly, RenovoRx may have encountered revenue challenges that affected profitability, leading to a flat EPS despite negative trends.
In conclusion, RenovoRx's flat EPS throughout 2023 can be attributed to a combination of factors, including financial performance and revenue challenges.